Clinical Scorecard: Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Population described in the source article. |
| Care Setting | Specify the type of oncology clinical trials (e.g., phase I, II). |
Key Highlights
- All 16 patients treated with TG4050 remained disease-free after a median follow-up of 41 months.
- Three of 16 patients in the control group experienced disease recurrence.
- The vaccine induced detectable T-cell responses in 73.3% of evaluated patients.
- Responses could be detected more than a year after the final dose.
- No unexpected safety findings were reported during long-term follow-up.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- C
- l
- a
- r
- i
- f
- y
- t
- h
- e
- s
- a
- f
- e
- t
- y
- p
- r
- o
- f
- i
- l
- e
- w
- i
- t
- h
- s
- p
- e
- c
- i
- f
- i
- c
- d
- a
- t
- a
- o
- r
- r
- e
- f
- e
- r
- e
- n
- c
- e
- s
- .
Patient & Prescribing Data
Detail how sequencing informs the vaccine design.
Clinical Best Practices
- best_practice_details
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
